Melanoma Activist

October 1, 2003

Chicago - An orally active small molecule inhibitor of Raf kinase, the first of its class to enter clinical trials, is well tolerated when combined with standard chemotherapy agents, and may have activity against metastatic melanoma, Keith T. Flaherty, M.D., said at the annual meeting of the American Society of Clinical Oncology.